STX-0119
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:406526
CAS#:851095-32-4
Description:STX-0119 is a potent STAT3 inhibitor. STX-0119 is an efficient therapeutic to overcome TMZ resistance in recurrent GBM tumors, and could be the next promising compound leading to survival prolongation. STX-0119 demonstrated strong inhibition of the expression of STAT3 target genes (c-myc, survivin, cyclin D1, HIF-1α and VEGF) and stem cell-associated genes (CD44, Nanog, nestin and CD133) as well as the induction of apoptosis in one stem-like cell line.
Price and Availability
STX-0119is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 406526Name: STX-0119CAS#: 851095-32-4Chemical Formula: C22H14N4O3Exact Mass: 382.10659Molecular Weight: 382.37Elemental Analysis: C, 69.10; H, 3.69; N, 14.65; O, 12.55
Synonym:STX0119; STX 0119; STX0119.
IUPAC/Chemical Name:N-(5-(furan-2-yl)-1,3,4-oxadiazol-2-yl)-2-phenylquinoline-4-carboxamide
InChi Key:MNPXTRXFUMGQLK-UHFFFAOYSA-N
InChi Code:InChI=1S/C22H14N4O3/c27-20(24-22-26-25-21(29-22)19-11-6-12-28-19)16-13-18(14-7-2-1-3-8-14)23-17-10-5-4-9-15(16)17/h1-13H,(H,24,26,27)
SMILES Code:O=C(C1=CC(C2=CC=CC=C2)=NC3=CC=CC=C13)NC4=NN=C(C5=CC=CO5)O4
Technical Data
Additional Information
References
1: Ashizawa T, Akiyama Y, Miyata H, Iizuka A,Komiyama M, Kume A, Omiya M, Sugino T, Asai A, Hayashi N, Mitsuya K,Nakasu Y, Yamaguchi K. Effect of the STAT3 inhibitor STX-0119 on theproliferation of a temozolomide-resistant glioblastoma cell line. Int JOncol. 2014 Jul;45(1):411-8. doi: 10.3892/ijo.2014.2439. Epub 2014 May12. PubMed PMID: 24820265.
2: Ashizawa T, Miyata H, Iizuka A, Komiyama M, Oshita C, Kume A, NogamiM, Yagoto M, Ito I, Oishi T, Watanabe R, Mitsuya K, Matsuno K, Furuya T,Okawara T, Otsuka M, Ogo N, Asai A, Nakasu Y, Yamaguchi K, Akiyama Y.Effect of the STAT3 inhibitor STX-0119 on the proliferation of cancerstem-like cells derived from recurrent glioblastoma. Int J Oncol. 2013Jul;43(1):219-27. doi: 10.3892/ijo.2013.1916. Epub 2013 Apr 23. PubMedPMID: 23612755.
3: Ashizawa T, Miyata H, Ishii H, Oshita C, Matsuno K, Masuda Y, FuruyaT, Okawara T, Otsuka M, Ogo N, Asai A, Akiyama Y. Antitumor activity ofa novel small molecule STAT3 inhibitor against a human lymphoma cellline with high STAT3 activation. Int J Oncol. 2011 May;38(5):1245-52.doi: 10.3892/ijo.2011.957. Epub 2011 Feb 28. PubMed PMID: 21369699.
4: Matsuno K, Masuda Y, Uehara Y, Sato H, Muroya A, Takahashi O,Yokotagawa T, Furuya T, Okawara T, Otsuka M, Ogo N, Ashizawa T, OshitaC, Tai S, Ishii H, Akiyama Y, Asai A. Identification of a New Series ofSTAT3 Inhibitors by Virtual Screening. ACS Med Chem Lett. 2010 Jul13;1(8):371-5. doi: 10.1021/ml1000273. eCollection 2010 Nov 11. PubMedPMID: 24900220; PubMed Central PMCID: PMC4007973.
